Sorafenib in the treatment of thyroid cancer

References

• American Association for Cancer Research. Cancer statistics highlight progress, challenges. Cancer Discov 2014;4:OF3
   Google Scholar
• Colonna M, Uhry Z, Guizard A, et al. Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France. Cancer Epidemiol 2015. [Epub ahead of print]
   Google Scholar
• Finlayson A, Barnes I, Sayeed S, et al. Incidence of thyroid cancer in England by ethnic group, 2001-2007. Br J Cancer 2014;110:1322-7
   Google Scholar
• Enewold LR, Zhou J, Devesa SS, et al. Thyroid cancer incidence among active duty U.S. military personnel, 1990-2004. Cancer Epidemiol Biomarkers Prev 2011;20:2369-76
   Google Scholar
• Schlumberger M, Chevillard S, Ory K, et al. Thyroid cancer following exposure to ionizing radiation. Cancer Radiother 2011;15:394-9
   Google Scholar
• Braverman ER, Blum K, Loeffke B, et al. Managing terrorism or accidental nuclear errors, preparing for iodine-131 emergencies: a comprehensive review. Int J Environ Res Public Health 2014;11:4158-200
   Google Scholar
• Antonelli A, Miccoli P, Derzhitski VE, et al. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg 1996;20:867-71
   Google Scholar
• Suzuki K, Yamashita S. Low-dose radiation exposure and carcinogenesis. Jpn J Clin Oncol 2012;42:563-8
   PubMed Web of Science ®Google Scholar
• Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol 2015;3:286-95
   PubMed Web of Science ®Google Scholar
• Jankovic B, Le KT, Hershman JM. Clinical Review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013;98:474-82
   Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol 2007;156:431-7
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-Related chronic hepatitis patients: A case-control study. Thyroid 2007;17:447-51
   PubMed Web of Science ®Google Scholar
• Ward EM, Thun MJ, Hannan LM, Jemal A. Interpreting cancer trends. Ann N Y Acad Sci 2006;1076:29-53
   PubMed Web of Science ®Google Scholar
• Miccoli P, Antonelli A, Spinelli C, et al. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 1998;133:89-93
   PubMedGoogle Scholar
• Haugen BR. Radioiodine remnant ablation: current indications and dosing regimens. Endocr Pract 2012;18:604-10
   Google Scholar
• Lamartina L, Cooper DS. Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view. Endocrine 2015. [Epub ahead of print]
   Google Scholar
• Antonelli A, Miccoli P, Ferdeghini M, et al. Role of neck ultra-sonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995;5:25-8
   PubMed Web of Science ®Google Scholar
• Antonelli A, Miccoli P, Fallahi P, et al. Role of neck ultra-sonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 2003;13:479-84
   PubMed Web of Science ®Google Scholar
• American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
   PubMed Web of Science ®Google Scholar
• Verburg FA, Mäder U, Tanase K, et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 2013;98:172-80
   Google Scholar
• Gruber JJ, Colevas AD. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20:113-26
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008;62:559-63
   PubMed Web of Science ®Google Scholar
• Sun XS, Sun SR, Guevara N, et al. Indications of external beam radiation therapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques. Crit Rev Oncol Hematol 2013;86:52-68
   PubMed Web of Science ®Google Scholar
• de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;5:535-60
   Google Scholar
• Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21:S37-43
   PubMed Web of Science ®Google Scholar
• Marotta V, Guerra A, Sapio MR, Vitale M. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 2011;165:499-507
   PubMed Web of Science ®Google Scholar
• Fagin JA. Challenging dogma in thyroid cancer molecular genetics- role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004;89:4264-6
   PubMed Web of Science ®Google Scholar
• Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006;155:645-53
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62
   PubMed Web of Science ®Google Scholar
• Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603-10
   PubMed Web of Science ®Google Scholar
• Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32:2718-26
   PubMed Web of Science ®Google Scholar
• Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist 2013;18:926-32
   PubMed Web of Science ®Google Scholar
• Marotta V, Franzese MD, Del Prete M, et al. Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opin Pharmacother 2013;14:1187-203
   PubMed Web of Science ®Google Scholar
• Tan A, Xia N, Gao F, et al. Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database Syst Rev 2010;3:CD007958
   Google Scholar
• Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76
   PubMed Web of Science ®Google Scholar
• Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol 2014;10:530-9
   PubMed Web of Science ®Google Scholar
• Tang C, Yang L, Wang N, et al. High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol 2014;7:3213-23
   Google Scholar
• Lim DJ, Baek KH, Lee YS, et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 2007;17:883-8
   Google Scholar
• Maxwell JE, Sherman SK, O’Dorisio TM, Howe JR. Medical management of metastatic medullary thyroid cancer. Cancer 2014;120:3287-301
   Google Scholar
• Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 2014;120:1920-31
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. RET TKI: potential role in thyroid cancers. Curr Oncol Rep 2012;14:97-104
   PubMed Web of Science ®Google Scholar
• Almeida MQ, Hoff AO. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol 2012;24:229-34
   PubMed Web of Science ®Google Scholar
• Lyra J, Vinagre J, Batista R, et al. mTOR activation in medullary thyroid carcinoma with RAS mutation. Eur J Endocrinol 2014;171:633-40
   Google Scholar
• Tamburrino A, Molinolo AA, Salerno P, et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res 2012;18:3532-40
   Google Scholar
• Lorusso PM, Eder JP. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin Investig Drugs 2008;17:1013-28
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer. Curr Genomics 2011;12:626-31
   PubMed Web of Science ®Google Scholar
• Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev 2010;31:578-99
   PubMed Web of Science ®Google Scholar
• Jasim S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics 2014;8:281-91
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Ruan M, Liu M, Dong Q, Chen L. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. J Clin Endocrinol Metab 2015;100:1771-9
   Google Scholar
• Fallahi P, Ferrari SM, Santini F, et al. Sorafenib and thyroid cancer. BioDrugs 2013;27:615-28
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw 2014;12:1671-80
   PubMed Web of Science ®Google Scholar
• Chen G, Nicula D, Renko K, Derwahl M. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol Rep 2015;33:1994-2000
   PubMed Web of Science ®Google Scholar
• Lagas JS, van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010;9:319-26
   PubMed Web of Science ®Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14
   PubMed Web of Science ®Google Scholar
• Lee JM, Sarosy GA, Annunziata CM, et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010;102:495-9
   PubMed Web of Science ®Google Scholar
• Duran I, Hotté SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:4849-57
   PubMed Web of Science ®Google Scholar
• Spigel DR, Burris HAIII, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small cell lung cancer. J Clin Oncol 2011;29:2582-9
   PubMed Web of Science ®Google Scholar
• Martinelli E, Troiani T, Morgillo F, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010;16:4990-5001
   PubMed Web of Science ®Google Scholar
• Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-9
   PubMed Web of Science ®Google Scholar
• Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon α2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-95
   PubMed Web of Science ®Google Scholar
• Egberts F, Gutzmer R, Ugurel S, et al. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 2011;22:1667-74
   PubMed Web of Science ®Google Scholar
• Toubert ME, Vercellino L, Faugeron I, et al. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid 2011;21:451-4
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34
   PubMed Web of Science ®Google Scholar
• Henderson YC, Ahn SH, Kang Y, Clayman GL. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 2008;14:4908-14
   PubMed Web of Science ®Google Scholar
• Koh YW, Shah MH, Agarwal K, et al. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocr Relat Cancer 2012;19:29-38
   PubMed Web of Science ®Google Scholar
• Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785-92
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31
   PubMed Web of Science ®Google Scholar
• Brose MS, Troxel AB, Redlinger M, et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. ASCO Annual Meeting, Orlando, Florida, 09
   Google Scholar
• Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson Experience. J Clin Endocrinol Metab 2010;95:2588-95
   PubMed Web of Science ®Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
   PubMed Web of Science ®Google Scholar
• Keefe SM, Troxel AB, Rhee S, et al. Phase II trial of sorafenib in patients with advanced thyroid cancer. ASCO Annual Meeting, Pennsylvania, Philadelphia; 2011
   Google Scholar
• Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Related Cancer 2012;19:209-16
   PubMed Web of Science ®Google Scholar
• Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012;167:643-50
   PubMed Web of Science ®Google Scholar
• Savvides P, Nagaiah G, Lavertu PN, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Tayroid 2013;23:600-4
   PubMed Web of Science ®Google Scholar
• Marotta V, Ramando V, Camera L, et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) 2013;78:760-7
   PubMed Web of Science ®Google Scholar
• Massicotte MH, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 2014;170:575-82
   PubMed Web of Science ®Google Scholar
• Benekli M, Yalcin S, Ozkan M, et al. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population. Onco Targets Ther 2014;8:1-5
   Google Scholar
• Gallo M, Michelon F, Castiglione A, et al. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine 2014. [Epub ahead of print].
   Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28
   PubMed Web of Science ®Google Scholar
• Bayer. Nexavar® versus placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer [ClinicalTrials.gov identifier: NCT00984282]. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT00984282?term=NCT00984282&rank=1
   Google Scholar
• Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011;7:617-24
   PubMed Web of Science ®Google Scholar
• Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-44
   PubMed Web of Science ®Google Scholar
• Chan D, Zheng Y, Tyner JW, et al. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol 2013;139:1507-14
   Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf) 2009;70:946-53
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2012;97:E528-36
   PubMed Web of Science ®Google Scholar
• Newell DR. Flasks, fibres and flanks–pre-clinical tumour models for predicting clinical antitumour activity. Br J Cancer 2001;84:1289-90
   PubMed Web of Science ®Google Scholar
• Schroyens W, Tueni E, Dodion P, et al. Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. Eur J Cancer 1990;26:834-8
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol 2008;159:283-91
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf) 2008;69:148-52
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, Fallahi P, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 2014;99:E572-E81
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:E288-E96
   PubMed Web of Science ®Google Scholar
• Marotta V, Colao A, Faggiano A. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine 2015. [Epub ahead of print].
   Google Scholar